TITLE

Darbepoetin Alfa Administration to Achieve and Maintain Target Hemoglobin Levels for 1 Year in Patients With Chronic Kidney Disease

PUB. DATE
September 2006
SOURCE
Mayo Clinic Proceedings;Sep2006, Vol. 81 Issue 9, p1188
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
23783477

 

Related Articles

  • Darbepoetin and risk of stroke. Elliott, William T. // Clinical Oncology Alert;Jan2010 Supplement 2, p2 

    The article reports on a study which indicates a link between therapy with darbepoetin alfa for asthma and increased risk of stroke in patients with chronic kidney disease and diabetes. The study involved more than 4,000 patients who were randomly assigned to darbepoetin alfa to achieve a...

  • Darbepoetin Alfa. Ibbotson, T.; Goa, K.L. // Drugs;Nov2001, Vol. 61 Issue 14, p2097 

    â–´ Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. â–´ In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately...

  • Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Ling, B.; Walczyk, M.; Agarwal, A.; Carroll, W.; Liu, W.; Brenner, R. // Clinical Nephrology;2005, Vol. 63 Issue 5, p327 

    Background: Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein that functions by the same mechanism as recombinant human erythropoietin (rHuEPO), but has a three-fold longer serum half-life. Reduction in the frequency of darbepoetin alfa administration would be beneficial to patients...

  • Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Kuwahara, Michio; Hasumi, Syoko; Mandai, Shintaro; Tanaka, Tomomi; Shikuma, Satomi; Akita, Wataru; Mori, Yoshihiro; Sasaki, Sei // Clinical & Experimental Nephrology;Oct2014, Vol. 18 Issue 5, p755 

    Background: Erythropoiesis-stimulating agents (ESAs) are standard therapy for chronic kidney disease (CKD) patients with renal anemia. However, few studies have compared the effects of different ESAs on anemia in identical pre-dialysis CKD patients. Methods: Seventy-nine patients who switched...

  • Darbepoetin Alfa (Aranespâ„¢) For Treating Anemia Associated With Chronic Kidney Disease. Kosier, June Hannay; Newton, Marian; Combest, Wendell; Gaines, Kaye K. // Urologic Nursing;Feb2003, Vol. 23 Issue 1, p77 

    Evaluates the use of darbepoetin alfa for treating anemia associated with chronic kidney disease. Decrease in the risk of blood transfusions; Maintenance of hemoglobin levels; Improvement of physical endurance in patients.

  • Darbepoetin Alfa: Its Use in Anemia Associated with Chronic Kidney Disease. Robinson, Dean M.; Easthope, Stephanie E. // BioDrugs;2005, Vol. 19 Issue 5, p327 

    Darbepoetin alfa (Aranesp®, Nespo®) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is...

  • A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. Pfeffer, Marc A.; Burdmann, Emmanuel A.; Chen, Chao-Yin; Cooper, Mark E.; De Zeeuw, Dick; Eckardt, Kai-Uwe; Feyzi, Jan M.; Ivanovich, Peter; Kewalramani, Reshma; Levey, Andrew S.; Lewis, Eldrin F.; McGill, Janet B.; McMurray, John J.V.; Parfrey, Patrick; Parving, Hans-Henrik; Remuzzi, Giuseppe; Singh, Ajay K.; Solomon, Scott D.; Toto, Robert // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2019 

    Background: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been...

  • Three-weekly an alternative to weekly darbepoetin alfa dosing?  // Reactions Weekly;6/18/2005, Issue 1056, p5 

    Discusses the use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Assessment of patients who randomly received darbepoetin alfa; Dosage of darbepoetin alfa required to achieve target haemoglobin levels; Side effects of the drug.

  • Every-Other-Week Darbepoetin Alfa in the Correction and Maintenance of Haemoglobin Levels in Elderly Patients with Chronic Kidney Disease: Post Hoc Subanalysis of Data from Two Clinical Trials. Krause, Michelle W.; Raja, Rasib; Agarwal, Anil; Silver, Marcia R.; Scarlata, Debra; Sciarra, Angela; Kewalramani, Reshma // Drugs & Aging;2009, Vol. 26 Issue 8, p665 

    Background: Anaemia is a common complication of chronic kidney disease (CKD) and is associated with increased rates of mortality and diminished quality of life in patients with CKD. Although extended dosing with darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), has been shown to be...

  • Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Warady, Bradley; Arar, Mazen; Lerner, Gary; Nakanishi, Arline; Stehman-Breen, Catherine // Pediatric Nephrology;Aug2006, Vol. 21 Issue 8, p1144 

    Darbepoetin alfa, an erythropoiesis-stimulating glycoprotein, has proved efficacious in the treatment of anemia of chronic kidney disease (CKD) in adult subjects. However, little information is available from pediatric populations. We conducted an open-label, non-inferiority, 28-week study...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics